These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 12804052)

  • 1. Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy.
    Wiseman GA; Leigh BR; Dunn WL; Stabin MG; White CA
    Cancer Biother Radiopharm; 2003 Apr; 18(2):253-8. PubMed ID: 12804052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Wiseman GA; White CA; Sparks RB; Erwin WD; Podoloff DA; Lamonica D; Bartlett NL; Parker JA; Dunn WL; Spies SM; Belanger R; Witzig TE; Leigh BR
    Crit Rev Oncol Hematol; 2001; 39(1-2):181-94. PubMed ID: 11418315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma.
    Wiseman GA; White CA; Stabin M; Dunn WL; Erwin W; Dahlbom M; Raubitschek A; Karvelis K; Schultheiss T; Witzig TE; Belanger R; Spies S; Silverman DH; Berlfein JR; Ding E; Grillo-López AJ
    Eur J Nucl Med; 2000 Jul; 27(7):766-77. PubMed ID: 10952488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma.
    Wiseman GA; Leigh B; Erwin WD; Lamonica D; Kornmehl E; Spies SM; Silverman DH; Witzig TE; Sparks RB; White CA
    Cancer; 2002 Feb; 94(4 Suppl):1349-57. PubMed ID: 11877765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia.
    Wiseman GA; Leigh BR; Erwin WD; Sparks RB; Podoloff DA; Schilder RJ; Bartlett NL; Spies SM; Grillo-López AJ; Witzig TE; White CA
    Cancer Biother Radiopharm; 2003 Apr; 18(2):165-78. PubMed ID: 12804042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
    J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma.
    Alcindor T; Witzig TE
    Curr Treat Options Oncol; 2002 Aug; 3(4):275-82. PubMed ID: 12074764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
    Cooney-Qualter E; Krailo M; Angiolillo A; Fawwaz RA; Wiseman G; Harrison L; Kohl V; Adamson PC; Ayello J; vande Ven C; Perkins SL; Cairo MS;
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
    Witzig TE; Flinn IW; Gordon LI; Emmanouilides C; Czuczman MS; Saleh MN; Cripe L; Wiseman G; Olejnik T; Multani PS; White CA
    J Clin Oncol; 2002 Aug; 20(15):3262-9. PubMed ID: 12149300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
    Marcus R
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin's lymphoma.
    Krasner C; Joyce RM
    Curr Pharm Biotechnol; 2001 Dec; 2(4):341-9. PubMed ID: 11762415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.
    Wiseman GA; Gordon LI; Multani PS; Witzig TE; Spies S; Bartlett NL; Schilder RJ; Murray JL; Saleh M; Allen RS; Grillo-López AJ; White CA
    Blood; 2002 Jun; 99(12):4336-42. PubMed ID: 12036859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma.
    Vaklavas C; Meredith RF; Shen S; Knox SJ; Micallef IN; Shah JJ; LoBuglio AF; Forero-Torres A
    Cancer Biother Radiopharm; 2013 Jun; 28(5):370-9. PubMed ID: 23530878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody.
    Wiseman GA; White CA; Witzig TE; Gordon LI; Emmanouilides C; Raubitschek A; Janakiraman N; Gutheil J; Schilder RJ; Spies S; Silverman DH; Grillo-López AJ
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3281s-3286s. PubMed ID: 10541376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.
    Shen S; Forero A; Meredith RF; Shah JJ; Knox SJ; Wiseman GA; Usrey ME; Lobuglio AF
    J Nucl Med; 2010 Jan; 51(1):150-7. PubMed ID: 20008989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.
    Wagner HN; Wiseman GA; Marcus CS; Nabi HA; Nagle CE; Fink-Bennett DM; Lamonica DM; Conti PS
    J Nucl Med; 2002 Feb; 43(2):267-72. PubMed ID: 11850494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.
    Esmaeli B; McLaughlin P; Pro B; Samaniego F; Gayed I; Hagemeister F; Romaguera J; Cabanillas F; Neelapu SS; Banay R; Fayad L; Wayne Saville M; Kwak LW
    Ann Oncol; 2009 Apr; 20(4):709-14. PubMed ID: 19150940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma.
    Chinn PC; Leonard JE; Rosenberg J; Hanna N; Anderson DR
    Int J Oncol; 1999 Nov; 15(5):1017-25. PubMed ID: 10536187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
    Zinzani PL; Tani M; Pulsoni A; Gobbi M; Perotti A; De Luca S; Fabbri A; Zaccaria A; Voso MT; Fattori P; Guardigni L; Ronconi S; Cabras MG; Rigacci L; De Renzo A; Marchi E; Stefoni V; Fina M; Pellegrini C; Musuraca G; Derenzini E; Pileri S; Fanti S; Piccaluga PP; Baccarani M
    Lancet Oncol; 2008 Apr; 9(4):352-8. PubMed ID: 18342572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.